PASI 90 response: the new standard in therapeutic efficacy for psoriasis
L Puig - Journal of the European Academy of Dermatology and …, 2015 - Wiley Online Library
In a non‐life‐threatening disease such as psoriasis, treatment goals should be referred to
the improvement in severity and extent of the disease and their impact on patients' perceived …
the improvement in severity and extent of the disease and their impact on patients' perceived …
Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis
X Xie, Y Wang, S Yao, Y Xia, H Luo, L Li… - Journal of …, 2022 - Taylor & Francis
Purpose This review article serves to assess the consistency of recommendations from
guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis …
guidelines on biologic agents for psoriasis, based on the quality evaluation of psoriasis …
ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice
E Vilarrasa, J Notario, X Bordas, A López-Ferrer… - Journal of the American …, 2016 - Elsevier
Background Biologic drug survival in psoriasis reflects long-term performance in real-life
settings. Previous studies have yielded inconsistent results. Objectives We sought to …
settings. Previous studies have yielded inconsistent results. Objectives We sought to …
Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized …
LS van der Schoot, JMPA van den Reek, L Grine… - Trials, 2021 - Springer
Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which
biologics are effective treatments. Dose reduction (DR) of the first generation biologics …
biologics are effective treatments. Dose reduction (DR) of the first generation biologics …
Проект междисциплинарных рекомендаций по диагностике, методам оценки степени активности воспалительного процесса, терапевтической …
ДИ Абдулганиева, АЛ Бакулев… - Альманах …, 2018 - cyberleninka.ru
Псориаз, псориатический артрит (ПсА) и воспалительные заболевания кишечника
(ВЗК) относятся к многофакторным хроническим иммуновоспалительным …
(ВЗК) относятся к многофакторным хроническим иммуновоспалительным …
[HTML][HTML] Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция …
ДИ Абдулганиева, АЛ Бакулев… - Альманах …, 2020 - cyberleninka.ru
Псориаз (Пс), псориатический артрит (ПсА) и воспалительные заболевания кишечника
(ВЗК) характеризуются прогрессирующим течением и нередко приводят к …
(ВЗК) характеризуются прогрессирующим течением и нередко приводят к …
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: a cross-sectional study in clinical practice
JM Carrascosa, I Garcia-Doval… - Journal of …, 2015 - Taylor & Francis
Introduction: Biologic medications increase dramatically the burden of a chronic and high
prevalent disease like psoriasis. The objective of the study was to quantify the use of dose …
prevalent disease like psoriasis. The objective of the study was to quantify the use of dose …
Treating psoriasis and psoriatic arthritis: position paper on applying the treat-to-target concept to Canadian daily practice
DD Gladman, Y Poulin, K Adams, M Bourcier… - The Journal of …, 2017 - jrheum.org
Objective. To develop preliminary treat-to-target (T2T) recommendations for psoriasis and
psoriatic arthritis (PsA) for Canadian daily practice. Methods. A task force composed of …
psoriatic arthritis (PsA) for Canadian daily practice. Methods. A task force composed of …
PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines
I Belinchon Romero, E Dauden… - Journal of …, 2022 - Taylor & Francis
Background Response to treatments in psoriasis can be assessed using the PASI response
50, 75, 90 or 100. Achieving a PASI 100 response would mean a complete resolution of the …
50, 75, 90 or 100. Achieving a PASI 100 response would mean a complete resolution of the …
Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review
Chronic inflammatory diseases represent a heterogeneous group of conditions that can
affect practically any organ or system. An increasing number of biologic agents have been …
affect practically any organ or system. An increasing number of biologic agents have been …